MUC17 and neoplasm: AMG 199 is bi-specific antibody targeting CD3 and MUC17 that was designed to engage CD3+ T cells to MUC17-positive G/GEJ cancer cells, mediate redirected tumor cell lysis, and induce T cell activation as well as proliferation.628 A phase I clinical trial is being conducted to test AMG 199 in patients with MUC17-positive G/GEJ cancer (NCT04117958).